Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B

Trial Profile

Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs ABX 203 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Abivax
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2016 This trial has been terminated in South Korea.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top